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To study the effect of disease duration on the clinical, neuropsychological and [18F]-deoxyglucose (FDG)
PET findings in patients with mixed type multiple system atrophy (MSA), this study included 16 controls and
37 mixed-type MSA patients with a shorter than a 3-year history of cerebellar or parkinsonian symptoms.
We classified the patients into three groups according to the duration of parkinsonian or cerebellar symptoms
(Group I=41 year; II = 13^24 months; III = 25^36 months). We performed UPDRS, international cooperative
ataxia rating scale (ICARS), and a neuropsychological test battery.We compared the FDG PET findings of each
group of patients with controls.Group I patients frequently hadmemory and frontal executive dysfunction.They
showed hypometabolism in the frontal cortex, anterior cerebellar hemisphere and vermis.They had parkinso-
nian motor deficits, but no basal ganglia hypometabolism. Group II and III patients frequently had multiple
domain cognitive impairments, and showed hypometabolism in the frontal and parieto-temporal cortices.
Hypometabolism of the bilateral caudate and the left posterolateral putamen was observed in Group II, and
whole striatum in Group III. In summary, the cortical hypometabolism begins in the frontal cortex and spreads
to the parieto-temporal cortex in MSA.This spreading pattern coincides with the progressive cognitive decline.
Early caudate hypometabolism may also contribute to the cognitive impairment. Parkinsonian motor deficits
precede putaminal hypometabolism that begins in its posterolateral part. Cerebellar hypometabolism occurs
early in the clinical courses and seems to be a relevant metabolic descriptor of cerebellar deficits.
Keywords: multiple system atrophy; cognitive impairment; positron emission tomography
Abbreviations: COWAT=controlled oral word association test; FDG=[18F]-deoxyglucose; FWHM=full-width
half-maximum; GCI=glial cytoplasmic inclusion; ICARS= international cooperative ataxia rating scale; IQR= interquartile
range; K-BNT=Korean version of the Boston naming test; MSA=multiple system atrophy; PET=positron emission
tomography; RCFT=Rey^Osterrieth complex figure test; SVLT=Seoul verbal learning test; TE=echo time; TR=repetition
time; UPDRS=unified Parkinson’s disease rating scale.
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Introduction
Patients with multiple system atrophy (MSA) usually
present with a variable mixture of parkinsonian, cerebellar,
pyramidal and autonomic symptoms and signs (Wenning
et al., 1997). Pathological studies of MSA show degenera-
tion of the substantia nigra, striatum, pallidum, cerebellum,
pontine nuclei, inferior olivary nucleus, pyramidal tract and
intermediolateral cell column of the spinal cord. In addition
to neuronal loss and gliosis, glial and neuronal inclusion
bodies occur in cerebral white matter and cortices,
as well as the striatonigral and olivopontocerebellar systems
(Papp et al., 1989; Papp and Lantos, 1994). However, post-
mortem pathological findings usually represent the end
result, but not the early evolution of the disease.
In vivo examinations of MSA patients with positron
emission tomography (PET) and single photon emission
computed tomography studies have shown hypometa-
bolism and hypoperfusion in the frontal cortex, striatum,
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cerebellum and brainstem (De Volder et al., 1989; Eidelberg
et al., 1993; Perani et al., 1995; Antonini et al., 1997;
Taniwaki et al., 2002; Juh et al., 2004; Cilia et al., 2005;
Matsui et al., 2005). However, most studies showed a
sum of neuronal functional changes in a small number
of patients without controlling for age, age at the onset of
disease, duration of disease and severity of clinical deficits.
Duration of the disease is an important factor that would
influence topographical distribution and severity of patho-
logical changes of neurodegenerative diseases (Apaydin
et al., 2002). To understand the pattern of evolution of
pathological changes, we investigated the effect of disease
duration on the findings of [18F]-deoxyglucose (FDG) PET
studies in patients with early MSA.
Patients
From July 2004 to May 2007, 75 MSA patients, who fulfilled
consensus criteria for possible or probable MSA (Gilman
et al., 1999), were admitted to Youngdong Severance Hospital,
Yonsei University, Seoul, Korea. Of these, 55 patients were
recruited with a shorter than a 3-year history of parkinsonian
or cerebellar symptoms, regardless of the duration of
autonomic symptoms. Of the 55 patients, 36 patients had
probable MSA and the remaining 19 patients had possible
MSA. During the follow-up period (mean = 12.9 months),
twelve of 19 patients with possible MSA developed autonomic
dysfunction sufficient for the diagnosis of probable MSA.
Of the 48 probable MSA patients, we excluded three patients
with pure cerebellar type MSA and five patients with pure
parkinsonian type MSA to include rather homogeneous
patients. We also excluded three patients with the Korean
version of Mini Mental State Examination (K-MMSE) score
lower than 24. Among the 37 patients with mixed type MSA,
19 patients (predominated by parkinsonism = 11, predomi-
nated by cerebellar deficits = 8) were receiving a single
levodopa treatment (mean daily dose = 739.5 mg) or a
combination with selegilline (daily dose = 5 mg).
Thus, this study included 37 patients with mixed type MSA
and 16 age-matched healthy controls [median age = 61.0
years, interquartile range (IQR) = 58.0–64.3 years, 5 males
and 11 females]. According to the duration of parkinsonian
or cerebellar symptoms, patients were classified into
three groups (Group I = duration 1 year or shorter; Group
II = duration between 13 and 24 months; Group III =
duration between 25 and 36 months). In all subjects, PET
studies were performed after written informed consents.
Methods
Evaluation of parkinsonian and cerebellar deficits
We measured the unified Parkinson’s disease rating scale
(UPDRS) motor score to assess the degree of parkinsonian deficits
and the international cooperative ataxia rating scale (ICARS)
scores to evaluate the severity of cerebellar deficits (Trouillas
et al., 1997).
Evaluation of cognitive function
Thirty-five of the 37 patients underwent a standardized neuro-
psychological test battery (Seoul Neuropsychological Screening
Battery) (Kang and Na, 2003). The battery consists of various
tests evaluating attention, language, praxis, four elements of
Gerstmann syndrome, visuoconstructional function, verbal and
visual memory, and frontal executive functions. Among them,
numerical tests were digit span test (forward and backward),
Korean version of the Boston Naming Test (K-BNT) (Kim and
Na, 1999), Rey–Osterrieth Complex Figure Test (RCFT; copying,
immediate and 20-min delayed recall and recognition), Seoul
Verbal Learning Test (SVLT; three learning-free recall trials of
12 words, 20-min delayed recall trial for these 12 items and
a recognition test), phonemic and semantic Controlled Oral Word
Association Test (COWAT) and Stroop Test (word and colour
reading of 112 items during a 2-min period). Age-, sex-, and
education-specific norms for each test based on 447 healthy
subjects were available.
We classified the cognitive function domain into four cate-
gories; memory, language, visuospatial function and frontal exec-
utive function and the pattern of cognitive dysfunction as single
domain or multiple domain impairments. Memory function
was evaluated with the delayed recall on the SVLT or the RCFT,
language function with K-BNT and visuospatial function with
copying score of the RCFT. The results of these numerical
cognitive tests were considered as abnormal when the scores were
below the 16th percentiles of the norms for the age-, sex- and
education-matched controls (Kang and Na, 2003). The patients
were considered to have frontal executive dysfunction if they
showed impairment in at least two of the following three tests:
motor executive function tests (contrasting programme, Go/no-go,
fist-edge-palm, alternating hand movement, alternative square
and triangle drawing and Luria loop), the COWAT and the
Stroop Test.
Brain FDGPETstudies
Acquisition of FDG PETscan images
After overnight fasting and withdrawal of all anti-parkinsonian
medications, FDG PET study was performed in a quiet and dimly
lit room with the subjects’ eyes open. After injecting 5.18 MBq/kg
of FDG into the antecubital vein, radial arterial blood was sampled
nine times at 5 to 10-s intervals for 1 min and then sampled
15 times at 30 s to 10 min of progressively increasing intervals.
The [18F]-radioactivity curve was obtained for quantification.
Using an Allegro PET scanner (Philips Medical Systems; gado-
linium oxyorthosilicate crystals), PET scanning was performed
at 45–55 min after injecting FDG. After 1.5 min of transmission,
17 min of emission and a final 1.5 min of transmission scans,
three-dimensional (3D) PET image was reconstructed by
3D-RAMLA (3D version of the row action maximum likelihood
algorithm).
Brain magnetic resonance imaging (MRI) studies
On the day of PET scan studies, brain MRI studies were performed
using 3D spoiled gradient-recalled (3D-SPGR) sequences on 3.0
Tesla MR scanner (Signa EXCITE, GE Medical Systems, Milwaukee,
WI). We obtained 160 slices of axial T1-weighted images with
a repetition time (TR) of 6.8 ms, a minimum of echo time (TE)
between 1.6 and 11.0 ms, a prep time of 300 msec, a flip angle of 20,
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a matrix of 256 256 and a slice thickness of 1 mm. The resulting
3D-MR image was reformatted parallel to the anterior and post-
erior commissures (AC-PC) line and centred at the midpoint of
AC-PC line. Finally, the image was resampled with a voxel size of
1 1 1 mm for normalization. We also obtained 32 slices of axial
T2-weighted images (TR = 5,250 ms, TE = 120 ms, flip angle = 90
,
matrix = 512 512 and slice thickness = 5 mm).
Pre-processing of PETand MR images
Individual MR images were used for spatial normalization of the
FDG PET image. Normalization was performed automatically with
the PFUS module in the software PMOD version 2.75 (PMOD
technologies Ltd., Zurich, Switzerland). The subject’s FDG PET
image was co-registered to individual MR image. Using affine
transformation and 12 non-linear iteration by 7 8 7 basis
function, the MR image was transformed to MNI-152 (Montreal
Neurological Institute) T1-weighted MRI template. During this
step, the individual transformation matrix was obtained and
applied to the co-registered FDG PET image. Finally, a spatially
normalized FDG PET image was obtained. The fitness of normal-
ized PET and MR images was verified visually in each normal-
ization step.
The parametric PET image was generated by the PMOD with
FDG-autoradiography method (lump constant = 0.437, k1 = 0.102,
k2 = 0.130, k3 = 0.062, k4 = 0.0068) (Huang et al., 1980). Subse-
quently, an isotropic Gaussian kernel of 12 mm full-width half-
maximum (FWHM) was applied to the parametric PET image to
improve the signal-to-noise ratio. Finally, this normalized and
smoothed parametric PET image was used for statistical analysis.
Statistical parametric mapping
Using the group comparison model covariated with age in SPM2
(Statistical Parametric Mapping; Wellcome Department of Cogni-
tive Neurology, London, UK) implemented to MATLAB 7.0
(MathWorks, Natick, MA), we compared the cerebral glucose
metabolism of each subgroup of MSA patients with the controls.
A family wise error (FWE)-corrected P-value 50.05 was consi-
dered statistically significant.
Results
Characteristics and clinical features
of patients (Table 1)
Of the 37 patients with mixed type MSA (22 men and
15 women), 17 patients had predominantly parkinsonian
features (MSA-P) and the other 20 patients predominantly
cerebellar deficits (MSA-C). There were 13 patients in
Group I (MSA-P = 4, MSA-C = 9), 12 patients in Group II
(MSA-P = 6, MSA-C = 6) and 12 patients in Group III
(MSA-P = 7, MSA-C = 5).
The ages of the patients (median age = 61.0 years,
IQR = 55.0–64.5 years) and controls were not different
(Mann–Whitney Test, P40.05). In addition, the ages of
the three groups of MSA patients [median (IQR) age: Group
I = 58.0 (51.0–65.0), Group II = 60.5 (49.8–69.0), Group
III = 61.0 (57.8–64.5) years] and controls were not signifi-
cantly different (Kruskal–Wallis Test, P= 0.851). The post hoc
comparison between each group and controls also did not
show difference (Mann–Whitney Test, P40.05). The median
(IQR) age of disease onset was 59.0 (53.5–62.5) years. The
median (IQR) of disease duration was 15.0 (12.0–27.0)
months [Group I = 8.0 (7.0–12.0) months, Group II = 15.5
(14.0–21.0) months, Group III = 32.0 (27.0–34.5) months].
The median (IQR) UPDRS motor score was 23.0
(19.0–33.5) and the median (IQR) ICARS score was 23.0
(18.0–34.5). There was significant difference in the UPDRS
motor scores among the three groups (Kruskal–Wallis Test,
P= 0.037). However, the ICARS scores were not signif-
icantly different among the three groups (Kruskal–Wallis
Test, P= 0.164).
Cognitive dysfunction (Table 2)
The median (IQR) K-MMSE score of the 37 patients was
29.0 (27.5–30.0). No patient satisfied the Diagnostic and
Statistical Manual of Mental Disorders, fourth edition
(DSM-IV) criteria for dementia.
Table 1 Clinical characteristics of the 37 patients with MSAwith different disease duration
Group I Group II Group III Total
n=13 n=12 n=12 n=37
MSA-P: MSA-C 4 : 9 6 : 6 7 : 5 17 : 20
Male: Female 9 : 4 7 : 5 6 : 6 22 : 15
Age (years) 58.0 (51.0^65.0) 60.5 (49.8^69.0) 61.0 (57.8^64.5) 61.0 (55.0^64.5)
Age of onset (years) 57.0 (50.5^64.5) 59.5 (48.5^67.3) 58.5 (55.8^61.8) 59.0 (53.5^62.5)
Duration (months) 8.0 (7.0^12.0) 15.5 (14.0^21.0) 32.0 (27.0^34.5) 15.0 (12.0^27.0)
UPDRS motor score 22.0 (16.5^25.0) 23.0 (18.3^32.3) 32.5 (20.8^39.5) 23.0 (19.0^33.5)
ICARS score 19.0 (14.0^30.5) 26.5 (18.5^34.8) 28.5 (20.5^37.5) 23.0 (18.0^34.5)
Urinary incontinence 6!9 8!10 8! 9 22! 28
Orthostatic hypotension 7!10 3! 4 8! 8 18! 22
Data are presented as median (interquartile range) and number of patients. The numbers shown in the urinary incontinence and
orthostatic hypotension lines represent the number of patients with autonomic dysfunction fulfilling the criteria of probable MSA
(Gilman et al., 1999) at the initial evaluation and follow-up visits. (n=number of patients; MSA-P=MSAwith predominantly parkinsonian
features; MSA-C=MSAwith predominantly cerebellar deficits; UPDRS=Unified Parkinson’s Disease Rating Scale; ICARS= International
Cooperative Ataxia Rating Scale).
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Among 35 patients who underwent neuropsychological
tests, only six (17.1%) showed a normal cognitive function
in all four domains tested (memory, frontal, visuospatial
and language functions). Four of them were in Group I,
and the remaining two were in Group II and III. Twenty-
nine patients (82.9%) had impairments in at least one
cognitive domain. Twenty-three patients (65.7%) had
memory impairment, 17 (48.6%) had frontal dysfunction,
nine (25.7%) had visuospatial dysfunction and two (5.7)
had language dysfunction. Fourteen of the 35 patients
(40.0%) had an impairment in a single domain (either
memory, frontal, visuospatial or language dysfunction).
Fifteen patients (42.9%) had impairments in at least two
domains. The individuals with multiple domain impair-
ments were found more frequently in Group III (six
patients, 60.0%) than in Group I (four patients, 30.8%) and
Group II (five patients, 41.7%).
T2-weighted brain MRI findings (Table 3)
Of the 37 patients with MSA, 34 patients had cerebellar
cortical atrophy and 23 patients had hot cross bun sign in
the pons. They were frequently found even in Group I
patients. About one-third of the patients showed more than
moderate degree of atrophy of the posterior putamen. The
putaminal rim sign (high signal intensity lines lateral to the
putamen) was observed in 13 of the 37 patients. It was
found in patients with duration longer than 12 months.
PET findings (Table 4, Figs 1 and 2)
Patients in Group I showed decreased glucose metabolism
in the right lateral and medial frontal cortex (Brodmann
area; BA6, 8, 9, 45 and 47), left lateral and medial frontal
cortex (BA6, 8, 9, 44 and 45), cerebellar vermis and bilateral
anterior cerebellar hemispheres. Group II patients showed
hypometabolism in the right lateral frontal cortex (BA4, 6,
8, 9, 10, 45 and 47), left lateral and medial frontal cortex
(BA4, 6, 8, 9, 10, 11, 45, 46 and 47), right superior, middle
and inferior temporal cortex (BA20, 21, 22 and 42), left
superior, middle and inferior temporal cortex (BA21, 37, 39
and 42), left fusiform gyrus (BA20 and 37), right post-
central gyrus (BA3, 1 and 2), left angular gyrus (BA39), left
precuneus (BA19) and right posterior cingulate cortex
(BA31). There were also hypometabolic areas involving
bilateral caudate nucleus and left posterolateral putamen.
Also, the cerebellar vermis and bilateral cerebellar hemi-
spheres were involved. Comparing to the Group II patients,
the basal ganglia hypometabolic area in the Group III
patients spread anteromedially to involve the entire puta-
men and globus pallidus.
Discussion
Cerebral cortical dysfunction in early MSA
FDG PET studies of MSA patients have reported normal or
reduced cerebral cortical glucose metabolism (De Volder
et al., 1989; Kume et al., 1992; Perani et al., 1995; Taniwaki
et al., 2002; Juh et al., 2004; Juh et al., 2005). However,
MSA patients with shorter than a 3-year history of
cerebellar or parkinsonian symptoms may show glucose
hypometabolism in the primary motor, premotor and pre-
frontal cortices (De Volder et al., 1989; Otsuka et al., 1996).
In the present study, MSA patients with disease duration
shorter than 1 year showed frontal hypometabolism, and
patients with disease durations longer than a year showed
hypometabolism in more widespread cerebral cortical areas
involving the frontal, temporal, parietal and cingulate
cortices. In contrast to patients with Parkinson’s disease,
the parieto-temporal association and occipital cortices were
preserved (Eidelberg et al., 1994; Hu et al., 2000). The
partial volume effect of the grey matter atrophy can affect
Table 2 Results of neuropsychological tests of the
35 patients with MSAwith different disease duration
Group I Group II Group III Total
K-MMSE score
n=13 n=12 n=12 n=37
29.0
(28.0^30.0)
29.0
(27.0^29.0)
28.0
(26.0^30.0)
29.0
(27.5^30.0)
Neuropsychological test
n=13 n=12 n=10 n=35
Normal 4 (30.8%) 1 (8.3%) 1 (10.0%) 6 (17.1%)
Single domain 5 (38.5%) 6 (50.0%) 3 (30.0%) 14 (40.0%)
Multiple domain 4 (30.8%) 5 (41.7%) 6 (60.0%) 15 (42.9%)
Impaired domain
M 7 (53.8%) 9 (75.0%) 7 (70.0%) 23 (65.7%)
E 4 (30.8%) 7 (58.3%) 6 (60.0%) 17 (48.6%)
V 2 (15.4%) 3 (25.0%) 4 (40.0%) 9 (25.7%)
L 1 (7.7%) 1 (8.3%) 0 (0%) 2 (5.7%)
Data are presented as median (interquartile range) and number
of patients. (n=number of patients; M=memory dysfunction;
E=executive dysfunction; V=visuospatial dysfunction;
L= language dysfunction; K-MMSE=Korean version of Mini
Mental State Examination).
Table 3 TheT2-weighted brain MRI findings related to MSA
Group I Group II Group III total
n=13 n=12 n=12 n=37
Atrophy of cerebellar cortex
Normal 2 (15%) 1 (8%) 0 3 (8%)
Mild 7 (54%) 4 (33%) 7 (58%) 18 (49%)
Moderate 4 (31%) 7 (58%) 5 (42%) 16 (43%)
Hot cross
bun sign 7 (54%) 7 (58%) 9 (75%) 23 (62%)
Atrophy of posterior putamen
Normal 1 (8%) 0 0 1 (3%)
Mild 10 (77%) 5 (42%) 8 (67%) 23 (62%)
Moderate 2 (15%) 6 (50%) 2 (17%) 10 (27%)
Severe 0 1 (8%) 2 (17%) 3 (8%)
Putaminal
rim sign 0 7 (58%) 6 (50%) 13 (35%)
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the glucose metabolism studied with the brain FDG
PET scan. However, in accordance with previous studies
(Brenneis et al., 2003, 2006), voxel-based morphometry of
the MR images of the patients included in this study
showed atrophy of the perisylvian and orbitofrontal cortical
areas. Therefore, cortical atrophy is unlikely to play a major
role in the cerebral cortical hypometabolism found in the
present study.
In pathological studies of MSA, cerebral cortical changes
have not received much attention and inconsistent results
on neuronal loss and gliosis of the cerebral cortex have
been reported. Some pathological studies showed mild to
moderate neuronal loss and adjacent white matter changes
in the superior and middle frontal gyri, supplementary
motor area, precentral gyrus, postcentral gyrus and inferior
parietal lobule (Spargo et al., 1996; Wakabayashi et al.,
1998; Konagaya et al., 1999; Tsuchiya et al., 2000; Su et al.,
2001). Neuronal loss and astrocytosis in the layer V of the
precentral gyrus was found, even in MSA patients with the
disease duration shorter than 3 years (Tsuchiya et al., 2000;
Su et al., 2001). However, a review of 203 pathologically
proven MSA patients reported that about 78.4% of the
patients had no abnormalities in the cerebral cortex, and
only 8.9% had moderate to severe abnormalities (Wenning
et al., 1997).
Glial cytoplasmic inclusions (GCIs) were found in the
frontal lobe, particularly in the supplementary motor,
cingulate, primary motor and premotor cortices (Papp
and Lantos, 1994). The distribution pattern of cerebral
cortical GCI is similar to that of cortical neuronal loss
(Papp et al., 1989; Papp and Lantos, 1994; Inoue et al.,
1997; Su et al., 2001). GCI is known to precede neuronal
loss and gliosis (Wenning et al., 1994; Inoue et al., 1997;
Wenning and Jellinger, 2005). Indeed, a patient who died
15 months after the onset of cerebellar type MSA had GCIs
in the precentral gyrus (Wakabayashi et al., 2005).
We postulate that the early widespread cortical glucose
hypometabolism observed in the present study is more
likely caused by cortical GCI than by cortical neuronal loss.
Another possible explanation may be damage to the afferent
Table 4 Results of statistical parametric mapping analysis showing brain areas of reduced glucose metabolism (family wise
error corrected P50.05)
Group I Group II Group III
BA x y z T BA x y z T BA x y z T
Rt superior frontal 6, 8, 9 20 39 48 6.3 6, 8, 9, 10 36 28 48 7.7 6, 8, 9, 10 20 11 64 10.5
Rt middle frontal 6, 8 44 22 43 6.0 10 42 58 10 6.8 6, 8, 9, 10, 46 24 22 58 8.5
Rt inferior frontal 45, 47 57 21 3 6.8 10, 45, 47 53 35 4 8.1 9, 45 61 9 22 5.4
Rt medial frontal 6 2 8 69 5.5 6, 10 12 8 69 7.3
Rt precentral 4, 6 50 1 53 6.4 6 40 8 63 7.9
Lt superior frontal 6, 8 4 43 46 6.3 6, 8, 9, 11 30 28 48 7.0 6, 8, 9 24 1 66 8.9
Lt middle frontal 6 28 15 60 5.3 6, 8, 46, 47 51 44 9 7.0 6, 9 28 5 64 9.4
Lt inferior frontal 9, 44, 45 59 14 1 5.1 9, 45, 47 55 31 2 6.1 9, 45 57 15 31 6.7
Lt medial frontal 8 2 47 42 6.2 10 0 61 6 5.9 6, 10 6 8 69 9.2
Lt precentral 6 48 7 57 5.6 4, 6 36 10 65 5.7 4, 6 30 8 67 8.3
Rt superior temporal 22, 42 69 15 10 8.7 22, 42 69 15 10 6.8
Rt middle temporal 21 57 0 34 7.4 21 65 2 2 6.3
Rt inferior temporal 20 65 32 20 6.1 20 61 9 31 5.7
Rt fusiform 20 63 9 28 5.7
Lt superior temporal 42 71 25 10 5.8 42 71 17 8 5.6
Lt middle temporal 21, 39 67 41 11 5.8 21 69 12 1 5.4
Lt inferior temporal 37 59 61 9 6.5 20 67 26 21 6.0
Lt fusiform 20, 37 50 61 22 6.9 20 63 15 30 7.4
Rt postcentral 3, 1, 2 65 20 34 6.9 3, 1 26 35 72 6.7
Rt precuneus 31 20 55 27 7.0
Lt postcentral 2, 5 38 41 65 5.7 2, 5 34 45 67 6.2
Lt precuneus 19 34 76 35 5.5
Lt angular 39 51 62 33 5.9
Rt posterior cingulate 31 16 51 25 5.4
Rt putamen 31 4 5 7.5
Rt caudate 16 14 9 6.2 19 20 8 5.7
Lt putamen 34 6 6 5.5 32 4 6 7.7
Lt caudate 16 14 7 6.6 19 14 9 5.3
Rt cerebellar hemisphere 48 52 29 6.1 38 79 23 6.5 36 55 46 6.3
Lt cerebellar hemisphere 48 52 26 5.1 24 83 24 6.5 46 48 28 5.7
cerebellar vermis 0 64 41 5.3 2 74 37 6.5 0 70 34 5.3
Rt=right, Lt= left, BA=Brodmann’s area; x, y, z=Talairach coordinate; T= t-value.
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cortical inputs arising from the subcortical nuclei (e.g. locus
ceruleus and substantia nigra) (Papp et al., 1989; Wenning
et al., 1994).
Previous studies on cognitive changes in patients with
MSA consistently reported frontal executive dysfunction
(Robbins et al., 1992, 1994; Monza et al., 1998; Berent
et al., 2002; Bak et al., 2005; Paviour et al., 2005; Bu¨rk et al.,
2006). Accordingly, the present study showed that about
half of the MSA patients develop frontal dysfunction within
a year after the onset of cerebellar or parkinsonian symp-
toms. These findings coincide with our FDG PET results
showing early medial and lateral frontal glucose
hypometabolism.
A previous study reported that about 40% of MSA
patients have memory impairment (Bak et al., 2005). In the
present study, 8 (22.9%) of 35 patients had a single
amnestic and 15 (42.9%) had multiple amnestic cognitive
impairments. The early memory impairment in patients
with MSA can be attributed to the hypometabolism of
the prefrontal and inferior frontal cortex (Tulving et al.,
1994; Buckner and Koutstaal, 1998; Buckner et al., 1999).
The proportion of patients with multiple amnestic cognitive
impairments was 30.8% in Group I, and it increased up to
60% in Group III.
Only a small proportion of patients with MSA are known
to have visuospatial dysfunction (Bak et al., 2005, 2006;
Bu¨rk et al., 2006). However, a longitudinal study showed
Fig. 1 The projection view (upper) and three-dimensional surface rendering images (lower) of statistical parametric mapping (SPM)
analysis show brain areas of reduced glucose metabolism (family wise error-corrected P50.05). (A=Group I, B=Group II, C=Group III)
Note that hypometabolic brain regions extend from the frontal cortex to the parieto-temporal cortex as the disease duration increases.
Fig. 2 The result of statistical parametric mapping co-registered
on theT1-weighted axial magnetic resonance brain image at the
level of the basal ganglia. (A) There is no hypometabolic basal
ganglia area in Group I patients. (B) There are hypometabolic
areas in the left posterolateral putamen and caudate nucleus of
Group II patients. (C) In Group III patients, hypometabolism
involves whole striatum and extends to the bilateral globi pallidi.
(family wise error-corrected P50.05; colour bar= t-value).
Duration and brain metabolism of MSA Brain (2008), 131, 438^446 443
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on Septem
ber 11, 2014
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
progressive deterioration of visuospatial function in MSA
(Soliveri et al., 2000). In the present study, no one had a
single visuospatial function domain impairment. However,
as the duration of disease increased, the proportion of
patients who had visuospatial dysfunction as a component
of their multiple domain impairments increased up to 40%.
This is in accordance with the spread of frontal hypo-
metabolism to involve parieto-temporal areas.
Language impairment has rarely been reported in
patients with MSA (Robbins et al., 1992; Bak et al.,
2005). Two (5.7%) of our patients had language impair-
ment. Our FDG PET studies showed preserved cortical
motor and sensory language areas, except left angular gyrus
involvement in Group II patients.
Basal ganglia dysfunction in early MSA
Although post-mortem pathological studies of MSA have
consistently reported damage to the basal ganglia, its evolu-
tion from early disease to the final outcome of neuro-
degeneration found at autopsy is largely unknown (Fearnley
and Lees, 1990; Wenning et al., 1995; Ozawa et al., 2004;
Jellinger et al., 2005). In previous literatures, we identified
post-mortem pathological findings of 10 MSA patients who
died within 3 years after the onset (Papp et al., 1989;
Fearnley and Lees, 1990; Kume et al., 1993; Su et al., 2001;
Wakabayashi et al., 2005). Except one patient with pure
olivopontocerebellar pathology (Wakabayashi et al., 2005),
the others had variable degree neuronal loss in the
putamen, caudate and substantia nigra.
Although our Group I patients had parkinsonian motor
deficits ranging from 9 to 38 on UPDRS motor score, they
showed no striatal hypometabolism. In MSA, calcineurin
positive medium spiny striatal neurons are depleted severely
in the dorsolateral part of the posterior putamen, but choline
acetyltransferase positive striatal neurons are preserved
(Sato et al., 2007). The nigrostriatal dopaminergic terminals
comprise less than one-fifth of the striatal synapses
(Tennyson et al., 1974; Pickel et al., 1981). Therefore, in
early MSA, the additive effect of selective striatal neuronal loss
and partial damage to the nigrostriatal neurons may cause
parkinsonian deficits, but too small changes in striatal
synaptic activity to be detected by FDG PET studies. A
multi-tracer PET study of the nine MSA patients also showed
no correlation between the degree of putaminal FDG uptake
and the severity of parkinsonian motor deficits (Antonini
et al., 1997). Another possible explanation may be non-
specific contamination of UPDRS motor scores by cerebellar
motor slowing (Tison et al., 2002).
In our study, as expected, Group II and III patients had
more severe parkinsonian motor deficits than Group I
patients. In Group II, glucose metabolism was reduced in
the caudate nucleus and posterolateral putamen. It is inter-
esting to note the early involvement of the posterolateral
putamen, where the somatic motor inputs from the cerebral
cortex and the nigrostriatal dopaminergic terminals are
connected (Hedreen and DeLong, 1991). The caudate
receives afferent fibres mainly from the prefrontal cortex
(Hedreen and DeLong, 1991; Lehericy et al., 2004).
Therefore, dysfunction of the caudate may contribute to
frontal executive dysfunction observed in our patients
(Alexander and Crutcher, 1990).
In Group III, the basal ganglia hypometabolic area
extended to involve whole putamen and globus pallidus.
Such changes may be caused by reduced activities of
afferent inputs to the pallidum and striatum, as well as loss
of striatal and pallidal intrinsic neurons (Papp et al., 1989).
Cerebellar dysfunction in early MSA
In MSA, there is neuronal loss in the pontine nuclei,
inferior olivary nucleus, cerebellar hemisphere and cerebel-
lar vermis (Papp and Lantos, 1994; Wenning et al., 1996;
Jellinger et al., 2005). There is a deposition of many GCIs
and extensive myelin loss in the cerebellar white matter,
middle cerebellar peduncle and basis pontis (Papp et al.,
1989; Papp and Lantos, 1994; Inoue et al., 1997; Tsuchiya
et al., 1998; Su et al., 2001; Wakabayashi et al., 2005). Such
changes are remarkable even in the early stage of the
disease, when the loss of Purkinje cells in the cerebellar
cortex is not evident or mild (Papp et al., 1989; Inoue et al.,
1997; Su et al., 2001; Wakabayashi et al., 2005).
In the present study, the cerebellar vermis and the
anterior cerebellar hemisphere were involved within 1 year
after the onset of parkinsonian or cerebellar symptoms.
These findings are in accordance with pathological studies
that have shown predominant involvement of anterior
cerebellar hemisphere (Kume et al., 1991; Wenning et al.,
1996).
In summary, this is the first in vivo FDG PET study
showing a pattern of progression of metabolic changes in
the brains of mixed type MSA patients. However, commu-
nity-based longitudinal FDG PET studies are needed to
verify the results of the present study.
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